Compare Moody's Corporation (MCO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs TG Therapeutics Inc — how do they compare? Moody's Corporation trades at $464 (market cap $79.44B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Moody's Corporation is far larger — about 9.7× TG Therapeutics Inc's market cap, and Moody's Corporation pays a 0.9% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and TG Therapeutics Inc for 16 Days on average.
| MCO | TGTX | |
|---|---|---|
Market Cap | $79.44B | $8.16B |
Volume | 526,684 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $539.61 | $59.06 |
52-Week Low | $412.23 | $26.94 |
Typical Hold Time | 132 Days | 16 Days |
Enterprise Value | $85.46B | $8.37B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $464.23, up 3.25% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 34.25% net margins and 80.15% ROE. Recent developments include a minority stake acquisition in PhilRatings and continued leadership in risk analytics, supported by 56% analyst buy ratings and a $536.40 consensus target.
Outlook remains positive given consistent revenue growth and expanding profitability, though technical resistance near $464 and high valuation multiples pose near-term risks. Long-term investors may find value in MCO's market position and dividend yield, but should monitor debt levels and macroeconomic sensitivity.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
